You are now leaving the website.

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.


Rheumatoid Arthritis: Plenty to Consider

Rheumatoid Arthritis: Plenty to Consider

As a result of significant investments in sophisticated, innovative research on new medications and treatments, scientists are beginning to unlock solutions to address chronic, incurable medical conditions like rheumatoid arthritis.

One area of this groundbreaking innovation is in the field of biologic medicines.

When being prescribed an innovator biologic medicine or biosimilar, patients, caregivers and physicians have a lot to consider.

In this video, we meet a rheumatoid arthritis patient and her physician who are discussing some of the important considerations around innovator biologics and biosimilars.

As any rheumatoid arthritis patient would need to do, they talk about the differences between the two types of drugs, cost of treatment and how the patient can investigate coverage through her employer’s private insurance benefit. This vital conversation also addresses the idea of switching medications and the importance of getting the exact medication the patient is prescribed.

If you have rheumatoid arthritis, speak to your doctor about your treatment, understand what is best for you and always make sure you are getting the medication you expect.

Do you want to link to our other external sites and leave

You are now leaving the Amgen Canada website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.